R&D channel feed

Bridge­Bio touts ad­di­tion­al AT­TR-CM drug da­ta in new analy­ses of Phase 3 tri­al

Last year

Im­muno­vant post­pones tri­al read­outs for its late-stage FcRn drug as it pri­or­i­tizes an­oth­er

Last year

Ar­row­head plots next steps for RNAi ther­a­pies af­ter mid-stage win in mixed hy­per­lipi­demia

Last year

Bio­haven’s au­toim­mune drug dis­ap­points in­vestors in study of healthy vol­un­teers 

Last year

J&J's ma­jor de­pres­sive dis­or­der drug hits end­points in Phase 3 tri­al

Last year

Ike­na On­col­o­gy weighs ‘strate­gic op­tions’ as it drops can­cer as­set, trims head­count to save cash

Last year
People

Arc­turus teas­es da­ta from small tri­al of in­hal­able cys­tic fi­bro­sis mR­NA ther­a­py, stock rock­ets 

Last year

As­traZeneca re­veals ear­ly da­ta for oral PC­SK9, touts PK edge over Mer­ck’s drug

Last year

Sec­ond en­gi­neered B cell ther­a­py en­ters the clin­ic, promis­ing to do in he­mo­phil­ia B what gene ther­a­pies can't

Last year
Cell/Gene Tx
FDA+

In­smed stock sky­rock­ets on Phase 3 lung dis­ease da­ta

Last year

NewAms­ter­dam says for­mer Am­gen car­dio drug re­duces heart dis­ease risk fac­tor

Last year

Duchenne mus­cu­lar dy­s­tro­phy drug flunks Phase 3 con­fir­ma­to­ry tri­al

Last year

Cor­rect­ed: As­traZeneca, Dai­ichi Sankyo’s TROP2 ADC boosts sur­vival in Phase 3 lung can­cer sub­group

Last year

#AS­CO24: Merus, tout­ing more Phase 2 da­ta, plots piv­otal head and neck can­cer tri­al in first-line set­ting

Last year

No­var­tis to seek ap­provals in two rare kid­ney dis­eases af­ter pos­i­tive Phase 3 tri­als

Last year

Ve­rastem's stock takes a hit af­ter shar­ing up­dat­ed fil­ing plans in ovar­i­an can­cer

Last year

#AS­CO24: A roundup of the lat­est da­ta from Merus, Mor­phoSys and oth­ers

Last year

HI-Bio out­lines da­ta that sparked $1.15B Bio­gen buy­out

Last year

No­vo re­ports 're­al­ly pow­er­ful' car­dio, death risk re­duc­tion for semaglu­tide in kid­ney dis­ease

Last year
Pharma

Zealand touts safe­ty of new ‘dou­ble-G’ drug de­spite mod­est weight loss in small tri­al

Last year

J&J plans for capped, flex­i­ble dos­ing af­ter four pa­tient deaths in ear­ly study of ac­tini­um prostate can­cer drug

Last year

Mer­ck, Kelun trum­pet Phase 3 breast can­cer da­ta for an­ti-TROP2 ADC

Last year

Af­ter $4B Take­da deal, Nim­bus lays out ‘grand’ hopes for its next-gen im­munother­a­py drug

Last year

Pfiz­er shares the ADC da­ta that con­vinced it to start a Phase 3 lung can­cer tri­al

Last year
Pharma
First page Previous page 43444546474849 Next page Last page
A service from the Financial Times